{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:35:36Z","timestamp":1790796936679,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:00:00Z","timestamp":1707523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:00:00Z","timestamp":1707523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006256","name":"Universit\u00e0 degli Studi dell\u2019Aquila","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006256","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>One of the aims of migraine prevention is to improve response to acute migraine treatments. The aim of the present study was to assess whether monoclonal antibodies targeting the CGRP pathway (CGRP-mAbs) can improve the perceived efficacy of acute treatments.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We included and followed up patients with chronic or episodic migraine from the Headache Centers of Avezzano-L\u2019Aquila and Naples treated with CGRP-mAbs from March 2021 to December 2022. All patients filled out the Migraine Treatment Optimization Questionnaire (MTOQ), the Headache Impact Test (HIT-6), and the Migraine Impact and Disability Assessment Scale (MIDAS) at baseline and 3\u20136\u00a0months after the start of treatment with CGRP-mAbs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Sixty-five patients (81.3%) completed the 6-month follow-up. Most patients were female (55, 84.6%), with a median age of 46\u00a0years (IQR 39\u201356). Median MTOQ score increased from 8 (interquartile range [IQR] 4\u201313) at baseline to 15 (IQR 11\u201317) at 3\u00a0months (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and 16 (IQR 13\u201317) at the 6-month follow-up (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Median migraine days over 90-day periods decreased from 40 (IQR 24\u201360) to 24 (IQR 15\u201330) at 3\u00a0months (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and to 20 (IQR 12\u201324) at 6\u00a0months (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Median monthly intake of acute medication decreased from 55 doses (IQR 29\u201380.5) to 24 doses (IQR 15\u201340) at 3\u00a0months and 18 doses (IQR 11\u201330) at 6\u00a0months (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>We showed that 6\u00a0months of preventive treatment with CGRP-mAbs led to a significantly better effectiveness of acute treatments, paralleled by decreased monthly migraine days and acute treatment intake.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10072-024-07380-4","type":"journal-article","created":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T05:02:06Z","timestamp":1707541326000},"page":"3305-3312","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Monoclonal antibodies targeting the calcitonin gene-related peptide pathway improve the effectiveness of acute medication\u2014a real-world study"],"prefix":"10.1007","volume":"45","author":[{"given":"Chiara","family":"Rosignoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Caponnetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnese","family":"Onofri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Trozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Tartaglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Silvestro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Sacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9501-4031","authenticated-orcid":false,"given":"Raffaele","family":"Ornello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,10]]},"reference":[{"key":"7380_CR1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s10194-020-01208-0","volume":"21","author":"TJ Steiner","year":"2020","unstructured":"Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z (2020) Migraine remains second among the world\u2019s causes of disability, and first among young women: findings from GBD2019. J Headache Pain 21:137","journal-title":"J Headache Pain"},{"key":"7380_CR2","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1111\/head.14206","volume":"61","author":"MJ Marmura","year":"2021","unstructured":"Marmura MJ, Diener HC, Cowan RP, Tepper SJ, Diamond ML, Starling AJ et al (2021) Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication-overuse headache. Headache 61:1421\u20131431","journal-title":"Headache"},{"key":"7380_CR3","first-page":"1157","volume":"27","author":"SJ Tepper","year":"2021","unstructured":"Tepper SJ, Fang J, Zhou L, Shen Y, Vo P, Abdrabboh A et al (2021) Effectiveness of erenumab and onabotulinumtoxinA on acute medication usage and health care resource utilization as migraine prevention in the United States. J Manag Care Spec Pharm 27:1157\u20131170","journal-title":"J Manag Care Spec Pharm"},{"key":"7380_CR4","first-page":"645","volume":"28","author":"A Ambrosini","year":"2022","unstructured":"Ambrosini A, Estemalik E, Pascual J, Rettiganti M, Stroud C, Day K et al (2022) Changes in acute headache medication use and health care resource utilization: results from a randomized, double-blind, placebo-controlled clinical trial evaluating galcanezumab in adults with treatment-resistant migraine (CONQUER). J Manag Care Spec Pharm 28:645\u2013656","journal-title":"J Manag Care Spec Pharm"},{"key":"7380_CR5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1185\/030079903125002676","volume":"20","author":"J Schim","year":"2004","unstructured":"Schim J (2004) Effect of preventive treatment with botulinum toxin type A on acute headache medication usage in migraine patients. Curr Med Res Opin 20:49\u201353","journal-title":"Curr Med Res Opin"},{"key":"7380_CR6","doi-asserted-by":"crossref","unstructured":"Halker Singh RB, Aycardi E, Bigal ME, Loupe PS, McDonald M, Dodick DW (2019) Sustained reductions in migraine days, moderate-to-severe headache days and days with acute medication use for HFEM and CM patients taking fremanezumab: post-hoc analyses from phase 2 trials. Cephalalgia 39(1):52\u201360","DOI":"10.1177\/0333102418772585"},{"key":"7380_CR7","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1007\/s13311-022-01230-x","volume":"19","author":"F Cohen","year":"2022","unstructured":"Cohen F, Yuan H, DePoy EMG, Silberstein SD (2022) The arrival of anti-CGRP monoclonal antibodies in migraine. Neurotherapeutics 19:922\u2013930","journal-title":"Neurotherapeutics"},{"key":"7380_CR8","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1016\/j.cell.2018.11.049","volume":"175","author":"L Edvinsson","year":"2018","unstructured":"Edvinsson L (2018) CGRP antibodies as prophylaxis in migraine. Cell 175:1719","journal-title":"Cell"},{"key":"7380_CR9","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s10194-023-01611-3","volume":"24","author":"N Vandenbussche","year":"2023","unstructured":"Vandenbussche N, Pisarek K, Paemeleire K (2023) Methodological considerations on real-world evidence studies of monoclonal antibodies against the CGRP-pathway for migraine: a systematic review. J Headache Pain 24:75","journal-title":"J Headache Pain"},{"key":"7380_CR10","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1136\/jnnp-2021-327480","volume":"93","author":"MD Ferrari","year":"2022","unstructured":"Ferrari MD, Reuter U, Goadsby PJ, da Silva P, Lima G, Mondal S, Wen S et al (2022) Two-year efficacy and safety of erenumab in participants with episodic migraine and 2\u20134 prior preventive treatment failures: results from the LIBERTY study. J Neurol Neurosurg Psychiatry 93:254\u2013262","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"7380_CR11","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","volume":"394","author":"MD Ferrari","year":"2019","unstructured":"Ferrari MD, Diener HC, Ning X, Galic M, Cohen JM, Yang R et al (2019) Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet 394:1030\u20131040","journal-title":"Lancet"},{"key":"7380_CR12","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/S1474-4422(20)30279-9","volume":"19","author":"WM Mulleners","year":"2020","unstructured":"Mulleners WM, Kim BK, L\u00e1inez MJA, Lanteri-Minet M, Pozo-Rosich P, Wang S et al (2020) Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol 19:814\u2013825","journal-title":"Lancet Neurol"},{"key":"7380_CR13","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S1474-4422(22)00185-5","volume":"21","author":"M Ashina","year":"2022","unstructured":"Ashina M, Lanteri-Minet M, Pozo-Rosich P, Ettrup A, Christoffersen CL, Josiassen MK et al (2022) Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol 21:597\u2013607","journal-title":"Lancet Neurol"},{"key":"7380_CR14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s10194-020-01143-0","volume":"21","author":"A Russo","year":"2020","unstructured":"Russo A, Silvestro M, Scotto di Clemente F, Trojsi F, Bisecco A, Bonavita S et al (2020) Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience. J Headache Pain 21:69","journal-title":"J Headache Pain"},{"key":"7380_CR15","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s10194-022-01415-x","volume":"23","author":"MT Driessen","year":"2022","unstructured":"Driessen MT, Cohen JM, Thompson SF, Patterson-Lomba O, Seminerio MJ, Carr K et al (2022) Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine. J Headache Pain 23:56","journal-title":"J Headache Pain"},{"key":"7380_CR16","doi-asserted-by":"publisher","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2013) The International Classification of Headache Disorders, 3rd edn (beta version). Cephalalgia 33(9):629\u2013808.\u00a0https:\/\/doi.org\/10.1177\/0333102413485658","DOI":"10.1177\/0333102413485658"},{"key":"7380_CR17","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1111\/j.1468-2982.2008.01786.x","volume":"29","author":"RB Lipton","year":"2009","unstructured":"Lipton RB, Kolodner K, Bigal ME, Valade D, L\u00e1inez MJ, Pascual J et al (2009) Validity and reliability of the Migraine-Treatment Optimization Questionnaire. Cephalalgia 29:751\u2013759","journal-title":"Cephalalgia"},{"key":"7380_CR18","doi-asserted-by":"publisher","first-page":"333102423117485","DOI":"10.1177\/03331024231174855","volume":"43","author":"R Ruscheweyh","year":"2023","unstructured":"Ruscheweyh R, Dresler T, F\u00f6rderreuther S, Gaul C, Gossrau G, J\u00fcrgens TP et al (2023) What do patients\u2019 efficacy and tolerability ratings of acute migraine medication tell us? Cross-sectional data from the DMKG Headache Registry. Cephalalgia 43:3331024231174855","journal-title":"Cephalalgia"},{"key":"7380_CR19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s10194-021-01250-6","volume":"22","author":"BK Kim","year":"2021","unstructured":"Kim BK, Chu MK, Yu SJ, Dell\u2019Agnello G, Han JH, Cho SJ (2021) Burden of migraine and unmet needs from the patients\u2019 perspective: a survey across 11 specialized headache clinics in Korea. J Headache Pain 22:45","journal-title":"J Headache Pain"},{"key":"7380_CR20","doi-asserted-by":"publisher","first-page":"S50","DOI":"10.1212\/WNL.65.12_suppl_4.S50","volume":"65","author":"RB Lipton","year":"2005","unstructured":"Lipton RB, Bigal ME, Stewart WF (2005) Clinical trials of acute treatments for migraine including multiple attack studies of pain, disability, and health-related quality of life. Neurology 65:S50-58","journal-title":"Neurology"},{"key":"7380_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.846717","volume":"13","author":"L Sette","year":"2022","unstructured":"Sette L, Caponnetto V, Ornello R, Ne\u017e\u00e1dal T, \u010ctrn\u00e1ct\u00e1 D, \u0160\u00edpkov\u00e1 J et al (2022) Acute medication use in patients with migraine treated with monoclonal antibodies acting on the CGRP pathway: results from a multicenter study and proposal of a new index. Front Neurol 13:846717","journal-title":"Front Neurol"},{"key":"7380_CR22","doi-asserted-by":"crossref","unstructured":"Dodick DW, Doty EG, Aurora SK, Ruff DD, Stauffer VL, Jedynak J, Dong Y, Pearlman EM (2021) Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine. Cephalalgia 41(3):340\u2013352","DOI":"10.1177\/0333102420966658"},{"key":"7380_CR23","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/nrneurol.2016.124","volume":"12","author":"HC Diener","year":"2016","unstructured":"Diener HC, Holle D, Solbach K, Gaul C (2016) Medication-overuse headache: risk factors, pathophysiology and management. Nat Rev Neurol 12:575\u2013583","journal-title":"Nat Rev Neurol"},{"key":"7380_CR24","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/S1474-4422(19)30146-2","volume":"18","author":"H-C Diener","year":"2019","unstructured":"Diener H-C, Dodick D, Evers S, Holle D, Jensen RH, Lipton RB et al (2019) Pathophysiology, prevention, and treatment of medication overuse headache. The Lancet Neurology 18:891\u2013902","journal-title":"The Lancet Neurology"},{"key":"7380_CR25","doi-asserted-by":"crossref","unstructured":"Mitsikostas D, Benedetti F (2019) Placebos and nocebos in headaches, 1st edn. Springer Cham, IX, p 142","DOI":"10.1007\/978-3-030-02976-0"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07380-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-024-07380-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07380-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T01:03:34Z","timestamp":1718327014000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-024-07380-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,10]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["7380"],"URL":"https:\/\/doi.org\/10.1007\/s10072-024-07380-4","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,10]]},"assertion":[{"value":"30 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Internal Review Board of the University of L\u2019Aquila with protocol number 10\/2021. All patients signed an informed consent to be included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"V.C. has received honoraria for participation in advisory boards sponsored by Novartis and speaker honoraria sponsored by Teva. M.S. has received speaker honoraria from Novartis, Teva, and Lilly. A.R. has received speaker honoraria from Allergan, Lilly, Novartis, Biogen, and Teva and serves as an associate editor of Frontiers in Neurology (Headache Medicine and Facial Pain session). S.S. reports personal fees as speaker or advisor by Abbott, Allergan-Abbvie, AstraZeneca, Boehringer, Eli Lilly, Lundbeck, Novartis, Novo Nordisk, Pfizer, Teva; research grants by Novartis, Uriach; president-elect European Stroke Organisation, second vice president of the European Headache Federation, specialty chief editor in Headache and Neurogenic Pain for Frontiers in Neurology, associate editor for the Journal of Headache and Pain, assistant editor for Stroke. RO reports personal fees from Novartis, Teva, Lilly, and Pfizer and non-financial support from AbbVie\/Allergan, Lilly, Novartis, and Teva. The other authors have nothing to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}